A Phase 4 interventional study of Butorphanol Injection and Saline in Colonoscopy, sponsored by Beijing Tiantan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-21.
Sponsored by Beijing Tiantan Hospital · Phase 4, Interventional, and Treatment
The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.
49 studies on the registry are indexed under Visceral Pain; 16 are open to participants now.
This study's enrollment of 203 is above the median of 72 across 45 interventional studies indexed under Visceral Pain.
Browse Visceral Pain studies →Beijing Tiantan Hospital is the lead sponsor of 481 studies on the registry; 287 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Butorphanol Injection
Drug: Saline
Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
visceral pain
VAS score of visceral pain
Time frame: 10 minutes after recovery
visceral pain at 20 and 30 minutes after recovery
VAS score of visceral pain
Time frame: 20 and 30 minutes after recovery
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Butorphanol